Australasian Gastro-Intestinal Trials Group
About
The Australasian Gastro-Intestinal Trials Group is a nonprofit organisation dedicated to improving health and quality of life for GI cancer patients by developing and conducting clinical trials across Australia. Since 1991, they've conducted 90 research studies providing over 9,930 patients access to promising new treatments. Their mission focuses on advancing treatments for digestive system cancers including esophageal, stomach, liver, pancreatic, bowel, and rectal cancers.
Tips for Applicants
As a clinical trials organisation rather than a traditional grantmaker, funding is directed toward their internal trial operations and researcher networks. Researchers interested in collaboration should have established clinical trial experience and connect through their clinical network. Community members can support through donations, fundraising, or participating in their Community Advisory Panel.
Giving Philosophy
This organisation funds and conducts clinical trials that test new treatments against current standards of care, prioritising research that improves survival rates and quality of life for GI cancer patients. They value collaboration with clinicians, researchers, and community advocates to bring innovative treatments to Australian patients faster.
ACNC Financial History
| Year | Grants Given | Revenue | Total Assets | Net Assets |
|---|---|---|---|---|
| FY2023 | $1.7M | $21.8M | $30.2M | $12.3M |
| FY2022 | — | $16.7M | $26.7M | $10.4M |
| FY2021 | $151K | $15.3M | $23.5M | $11.5M |
| FY2020 | $56K | $10.2M | $17.5M | $10.5M |
| FY2019 | $119K | $8.4M | $13.9M | $7.6M |
| FY2018 | $5K | $5.3M | $13.5M | $7.4M |
| FY2017 | — | $5.8M | $13.6M | $6.7M |
| 7yr total | $2.1M | Source: ACNC Annual Information Statements | ||